Read by QxMD icon Read

alginate hydrogel heart failure

Claire McCune, Peter McKavanagh, Ian B A Menown
INTRODUCTION: Multiple significant, potentially practice changing clinical trials in cardiology have been conducted and subsequently presented throughout the past year. METHODS: In this paper, the authors have reviewed and contextualized significant cardiovascular clinical trials presented at major international conferences of 2015 including American College of Cardiology, European Association for Percutaneous Cardiovascular Interventions, American Diabetes Association, European Society of Cardiology, Transcatheter Cardiovascular Therapeutics, Heart Rhythm Congress, and the American Heart Association Scientific Sessions...
December 2016: Cardiology and Therapy
Douglas L Mann, Randall J Lee, Andrew J S Coats, Gheorghe Neagoe, Dinu Dragomir, Enrico Pusineri, Massimo Piredda, Luca Bettari, Bridget-Anne Kirwan, Robert Dowling, Maurizio Volterrani, Scott D Solomon, Hani N Sabbah, Andy Hinson, Stefan D Anker
AIMS: AUGMENT-HF was an international, multicentre, prospective, open-label, randomized, controlled evaluation testing the hypothesis that Algisyl (injectable calcium alginate hydrogel) is superior to standard medical therapy (SMT) for improving functional capacity and clinical outcomes in patients with advanced heart failure (HF). We previously reported results following 6 months of follow-up. This report presents the results from 1 year of extended follow up for this clinical trial...
March 2016: European Journal of Heart Failure
Pierpaolo Pellicori, Andrew L Clark
This article provides an overview on the key trials relevant to the pathophysiology, prevention, and treatment of heart failure (HF) presented at the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) annual meeting held in Seville, Spain in May 2015. Trials reported include AUGMENT-AF (myocardial injections of calcium-alginate hydrogel), a propensity score-matched study of renin-angiotensin system antagonists in patients with HF and severe renal dysfunction, HARMONIZE (sodium zirconium cyclosilicate used to bind potassium), TITRATION, comparing two regimes for introducing LCZ696, STOP-HF, a trial of intramyocardial stromal cell-derived factor-1, MOOD-HF (escitalopram for patients with heart failure and depression), and LION HEART, a trial of intermittent levosimendan therapy...
September 2015: European Journal of Heart Failure
Gregory B Lim
No abstract text is available yet for this article.
August 2015: Nature Reviews. Cardiology
Stefan D Anker, Andrew J S Coats, Gabriel Cristian, Dinu Dragomir, Enrico Pusineri, Massimo Piredda, Luca Bettari, Robert Dowling, Maurizio Volterrani, Bridget-Anne Kirwan, Gerasimos Filippatos, Jean-Louis Mas, Nicolas Danchin, Scott D Solomon, Randall J Lee, Frank Ahmann, Andy Hinson, Hani N Sabbah, Douglas L Mann
AIMS: AUGMENT-HF was an international, multi-centre, prospective, randomized, controlled trial to evaluate the benefits and safety of a novel method of left ventricular (LV) modification with alginate-hydrogel. METHODS: Alginate-hydrogel is an inert permanent implant that is directly injected into LV heart muscle and serves as a prosthetic scaffold to modify the shape and size of the dilated LV. Patients with advanced chronic heart failure (HF) were randomized (1 : 1) to alginate-hydrogel (n = 40) in combination with standard medical therapy or standard medical therapy alone (Control, n = 38)...
September 7, 2015: European Heart Journal
Norbert Frey, Axel Linke, Tim Süselbeck, Jochen Müller-Ehmsen, Paul Vermeersch, Danny Schoors, Mark Rosenberg, Florian Bea, Shmuel Tuvia, Jonathan Leor
BACKGROUND: We aimed to test, for the first time, the feasibility of intracoronary delivery of an innovative, injectable bioabsorbable scaffold (IK-5001), to prevent or reverse adverse left ventricular remodeling and dysfunction in patients after ST-segment-elevation myocardial infarction. METHODS AND RESULTS: Patients (n=27) with moderate-to-large ST-segment-elevation myocardial infarctions, after successful revascularization, were enrolled. Two milliliters of IK-5001, a solution of 1% sodium alginate plus 0...
December 2014: Circulation. Cardiovascular Interventions
Xiaojuan Wei, Tingfei Xi, Qisheng Gu, Yufeng Zheng
OBJECTIVE: To review the current situation of alginate-based biomedical materials, especially focus on the clinical strategies and research progress in the clinical applications and point out several key issues that should be concerned about. METHODS: Based on extensive investigation of domestic and foreign alginate-based biomedical materials research and related patent, literature, and medicine producted, the paper presented the comprehensive analysis of its research and development, application status, and then put forward several new research directions which should be focused on...
August 2013: Chinese Journal of Reparative and Reconstructive Surgery
Hani N Sabbah, Mengjun Wang, Ramesh C Gupta, Sharad Rastogi, Itamar Ilsar, Michael S Sabbah, Smita Kohli, Sam Helgerson, Randall J Lee
OBJECTIVES: The study tested the hypothesis that augmentation of the left ventricular (LV) wall thickness with direct intramyocardial injections of alginate hydrogel implants (AHI) reduces LV cavity size, restores LV shape, and improves LV function in dogs with heart failure (HF). BACKGROUND: Progressive LV dysfunction, enlargement, and chamber sphericity are features of HF associated with increased mortality and morbidity. METHODS: Studies were performed in 14 dogs with HF produced by intracoronary microembolizations (LV ejection fraction [EF] <30%)...
June 2013: JACC. Heart Failure
Lik Chuan Lee, Samuel T Wall, Doron Klepach, Liang Ge, Zhihong Zhang, Randall J Lee, Andy Hinson, Joseph H Gorman, Robert C Gorman, Julius M Guccione
BACKGROUND: Left ventricular (LV) wall stress reduction is a cornerstone in treating heart failure. Large animal models and computer simulations indicate that adding non-contractile material to the damaged LV wall can potentially reduce myofiber stress. We sought to quantify the effects of a novel implantable hydrogel (Algisyl-LVR™) treatment in combination with coronary artery bypass grafting (i.e. Algisyl-LVR™+CABG) on both LV function and wall stress in heart failure patients. METHODS AND RESULTS: Magnetic resonance images obtained before treatment (n=3), and at 3 months (n=3) and 6 months (n=2) afterwards were used to reconstruct the LV geometry...
October 3, 2013: International Journal of Cardiology
Todd D Johnson, Karen L Christman
INTRODUCTION: Heart failure following myocardial infarction (MI) impacts millions of people each year in the US. The field of tissue engineering has developed several potential therapies for treating MI including injectable acellular hydrogels. These injectable biomaterials can either be synthetic or naturally derived, and have the potential to be delivered minimally invasively. AREAS COVERED: This review covers the different methods of delivery and presents the initial work on the use of injectable biomaterial scaffolds alone to improve cardiac function post-MI...
January 2013: Expert Opinion on Drug Delivery
Nicola C Hunt, Richard M Shelton, Deborah J Henderson, Liam M Grover
Vascularization of engineered or damaged tissues is essential to maintain cell viability and proper tissue function. Revascularization of the left ventricle (LV) of the heart after myocardial infarction is particularly important, since hypoxia can give rise to chronic heart failure due to inappropriate remodeling of the LV after death of cardiomyocytes (CMs). Fibroblasts can express vascular endothelial growth factor (VEGF), which plays a major role in angiogenesis and also acts as a chemoattractant and survival factor for CMs and cardiac progenitors...
April 2013: Tissue Engineering. Part A
Randall J Lee, Andy Hinson, Sam Helgerson, Robert Bauernschmitt, Hani N Sabbah
Heart failure continues to be a major health care concern with relatively few options for severely advanced heart failure patients. The hallmark of heart failure is the progressive dilatation of the left ventricle, thinning of the left ventricular wall leading to increased wall stress and increased myocardial oxygen consumption. Applying Laplace's law to the failing dilated ventricle, left ventricular augmentation utilizes a tissue engineering strategy to increase wall thickness and reduce chamber diameter, resulting in a decrease in wall stress and improved left ventricular function...
2013: Cell Transplantation
Ting Chu Ken Liu, Siti Ismail, Orlaith Brennan, Conn Hastings, Garry P Duffy
Anthracyclines are powerful drugs available for the treatment of neoplastic diseases. Unfortunately, these chemotherapy agents cause cardiomyopathy and congestive heart failure. Doxorubicin (DOX) is a widely used anthracycline and evidence indicates that DOX-induced cardiotoxicity can be viewed as a stem cell disease, whereby the formation of reactive oxygen species (ROS) by DOX is seen to predominantly hinder cardiac stem cell (CSC) regenerative capability. Acute, early-onset and late-onset cardiotoxicity have been described and this may be reversible by the local administration of CSCs, which regenerate myocardial tissue and rescue the failing heart...
April 2013: Journal of Tissue Engineering and Regenerative Medicine
Jayarama Reddy Venugopal, Molamma P Prabhakaran, Shayanti Mukherjee, Rajeswari Ravichandran, Kai Dan, Seeram Ramakrishna
World Health Organization estimated that heart failure initiated by coronary artery disease and myocardial infarction (MI) leads to 29 per cent of deaths worldwide. Heart failure is one of the leading causes of death in industrialized countries and is expected to become a global epidemic within the twenty-first century. MI, the main cause of heart failure, leads to a loss of cardiac tissue impairment of left ventricular function. The damaged left ventricle undergoes progressive 'remodelling' and chamber dilation, with myocyte slippage and fibroblast proliferation...
January 7, 2012: Journal of the Royal Society, Interface
Jiashing Yu, Yiping Gu, Kim T Du, Shirley Mihardja, Richard E Sievers, Randall J Lee
Congestive heart failure (CHF) is a chronic disease with a high mortality rate. Managing CHF patients has been one of the most severe health care problems for years. Scaffold materials have been predominantly investigated in acute myocardial infarction (MI) studies and have shown promising improvement in LV function. In this study we examined whether surface modification of a biomaterial can influence the myocardial microenvironment and improve myocardial function in a rodent model of ischemic cardiomyopathy...
February 2009: Biomaterials
Natali Landa, Liron Miller, Micha S Feinberg, Radka Holbova, Michal Shachar, Inbar Freeman, Smadar Cohen, Jonathan Leor
BACKGROUND: Adverse cardiac remodeling and progression of heart failure after myocardial infarction are associated with excessive and continuous damage to the extracellular matrix. We hypothesized that injection of in situ-forming alginate hydrogel into recent and old infarcts would provide a temporary scaffold and attenuate adverse cardiac remodeling and dysfunction. METHODS AND RESULTS: We developed a novel absorbable biomaterial composed of calcium-crosslinked alginate solution, which displays low viscosity and, after injection into the infarct, undergoes phase transition into hydrogel...
March 18, 2008: Circulation
P Senet, S Meaume
UNLABELLED: LOCAL CARE: Local antiseptics and antibiotics must be avoided to preserve the local bacterial ecosystem of the wound. If surgical debridement is not possible, hypercolloid, alginate or hydrogel dressings should be applied to achieve natural autolytic cleansing. The budding and epithelization phases are also treated either with oily or humid dressings or more modern hypercellular, hydrocolloid and polyurethane film dressings. Other treatments under evaluation include physical means (negative pressure, electrical stimulation) or use of recombinant growth factors...
October 30, 1999: La Presse Médicale
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"